Ticker: WAT

Waters Corporation

Healthcare Healthcare Medical - Diagnostics & Research
Price 401.00
Reco Buy Potential 72 Risk 37 Updated 2026-09-10

Forecast impact

neutral
Target +18.6% target fill 84.3%
Reaction D5 -0.80% · D10 -1.04%
Impact Potential 0 · Risk 0 valid until 2026-09-26

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Waters Corporation specializes in analytical instruments and software for the life sciences, pharmaceutical, and chemical industries. Its core products include liquid chromatography and mass spectrometry systems, along with related consumables and services. Major business segments encompass Waters Division, which focuses on laboratory instruments, and TA Instruments, which provides thermal analysis and rheology solutions. The primary revenue sources are from instrument sales, consumables, and service contracts.

Investment Profile

The investment profile of Waters Corporation is more aligned with value investors, given its established market presence and focus on stable revenue streams. The company exhibits moderate growth potential, but with heightened risk factors that may deter conservative investors. This profile suggests a balanced approach for those considering long-term investment strategies.

Fundamental metrics (experimental) Updated: 2026-09-08
EPS (TTM) — earnings per share for the last 12 months, $
4.02
Revenue QoQ — quarter-over-quarter revenue growth
29.8%
EPS surprise
16.9%
20d volatility
1.4%
last ex-date
1996-11-26
AI recommendation changes
Date Before After Reason
2026-07-23 Hold Buy Strong fundamentals, but mixed momentum signals present uncertainty.
2026-07-21 Buy Hold Weak momentum and high risk overshadow positive fundamentals.
2026-07-11 Hold Buy Strong revenue growth, but mixed momentum signals.
Analyst forecasts
Date Analyst Action Target Price Then
2026-09-09 UBS Update — → 490 402.91
2026-08-27 Piper Sandler Rating Upgraded — → 480 414.17
2026-08-05 Morgan Stanley Target Raised 390 → 430 400.032
News Page 1 of 1